# Hour 06: 06:00-06:59 - Ramp-Up Period

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## Hour Summary

Hour 06 marks the beginning of the morning ramp-up period with 6 new patient
arrivals across diverse cancer types and procedures. This is the highest
single-hour intake so far in the simulation, reflecting on-demand scheduling
flexibility as patients select early morning appointments. The hour includes
the first adverse event near-miss of the trial: a vasovagal response during
ablation preparation for PAT-ODMND-0022. Three overnight patients are
discharged, and a pediatric patient wakes to begin a morning companion
robot interaction session.

## Site Status at 06:00

- Total patients on-site: 8 (P0003, P0005, P0013, P0014, P0015, P0016, P0017, plus carryover)
- Active procedures: 0 (between-hour transition)
- Robots in active mode: 1 (COMPN-03 passive monitoring for P0005)
- Robots in standby mode: 28
- Robots in maintenance: 0
- Queue length: 0 across all stations
- Site safety officer on duty: SSO-D1 (day shift handover at 06:00)

## New Patient Arrivals

| Patient ID | Time | Age | Sex | Cancer Type | Stage/Grade | ECOG | Robot Assigned |
|-----------|------|-----|-----|-------------|-------------|------|----------------|
| PAT-ODMND-0018 | 06:05 | 42 | F | Meningioma | Stage I | 0 | RT Positioning (RTPOS-02) |
| PAT-ODMND-0019 | 06:12 | 56 | M | SCLC | Stage III | 1 | RT Motion-Tracking (TRACK-03) |
| PAT-ODMND-0020 | 06:20 | 11 | M | Pediatric osteosarcoma | - | 1 | Humanoid (HUMAN-01), then Rehab (REHAB-02) |
| PAT-ODMND-0021 | 06:30 | 29 | F | Forearm sarcoma | Grade II | 0 | Cobot (COBOT-03) |
| PAT-ODMND-0022 | 06:40 | 68 | M | HCC | Stage II | 1 | Steerable Needle (STEER-01) |
| PAT-ODMND-0023 | 06:52 | 73 | F | NSCLC adenocarcinoma | Stage IV | 2 | Imaging (IMAGE-01) |

Patient PAT-ODMND-0018 is a 42-year-old female with Stage I meningioma
presenting for brain radiotherapy positioning and treatment. ECOG 0. Treatment
plan: 1.8 Gy fraction. She selected the early morning slot to minimize
disruption to her work schedule.

Patient PAT-ODMND-0019 is a 56-year-old male with Stage III small-cell lung
cancer presenting for radiotherapy with motion tracking. ECOG 1. He is
receiving investigational atezolizumab combination therapy per IND protocol,
administered prior to RT. Treatment plan: 2 Gy fraction with respiratory
gating.

Patient PAT-ODMND-0020 is an 11-year-old male with pediatric osteosarcoma
presenting for humanoid-assisted physical therapy followed by rehabilitation
exoskeleton session. ECOG 1. Parent/guardian present per 21 CFR Part 50
Subpart D pediatric protections. This is a combined therapy and rehab session
to support limb function during ongoing chemotherapy.

Patient PAT-ODMND-0021 is a 29-year-old female with Grade II forearm sarcoma
presenting for cobot-assisted biopsy. ECOG 0. Tissue sampling for
histopathological grading confirmation.

Patient PAT-ODMND-0022 is a 68-year-old male with Stage II hepatocellular
carcinoma presenting for steerable needle ablation. ECOG 1. This is a 45-minute
procedure beginning at 06:42, extending into Hour 07.

Patient PAT-ODMND-0023 is a 73-year-old female with Stage IV NSCLC
adenocarcinoma presenting for imaging assessment. ECOG 2. Liver metastasis
surveillance scan.

## Continuing Patients

| Patient ID | Age | Sex | Cancer Type | Status |
|-----------|-----|-----|-------------|--------|
| PAT-ODMND-0003 | 61 | M | Mediastinal tumor | Post-surgical recovery, physician assessment 06:30 |
| PAT-ODMND-0005 | 8 | M | Pediatric ALL | Wakes at 06:15, COMPN-03 morning interaction mode |
| PAT-ODMND-0014 | - | - | - | Continuing from prior hour |
| PAT-ODMND-0017 | - | - | - | Continuing from prior hour |

## Active Procedures This Hour

### RT Positioning Session (06:08-06:28)
- Patient: PAT-ODMND-0018
- Robot: RTPOS-02 (RT Positioning, Instance 2)
- Vault: Radiotherapy Vault 2
- Procedure: Brain RT positioning and 1.8 Gy fraction delivery for meningioma
- Duration: 20 minutes (positioning 5 min, mask fitting 3 min, treatment 10 min, exit 2 min)
- Isocenter offset: 0.9 mm (within 1.5 mm tolerance)
- Couch corrections: Lateral 0.4 mm, longitudinal 0.3 mm, vertical 0.2 mm
- Outcome: Successful completion. Full dose delivered.

Minute-by-minute summary:
- 06:08 - Patient positioned on couch, thermoplastic mask applied
- 06:10 - CBCT verification scan acquired, auto-registration performed
- 06:11 - RTPOS-02 applies couch corrections (0.9 mm composite offset)
- 06:13 - Verification image confirms alignment within tolerance
- 06:14 - Beam-on, field 1 (lateral). 0.6 Gy delivered.
- 06:18 - Field 1 complete. Gantry rotation.
- 06:19 - Beam-on, field 2 (anterior oblique). 0.6 Gy delivered.
- 06:22 - Field 2 complete. Gantry rotation.
- 06:23 - Beam-on, field 3 (posterior oblique). 0.6 Gy delivered.
- 06:26 - Field 3 complete. Total: 1.8 Gy delivered.
- 06:27 - Mask removed, patient assisted to seated position
- 06:28 - Patient exits vault. Procedure complete.

### RT Motion-Tracking Session (06:18-06:36)
- Patient: PAT-ODMND-0019
- Robot: TRACK-03 (RT Motion-Tracking, Instance 3)
- Vault: Radiotherapy Vault 3
- Procedure: Lung RT with respiratory gating, 2 Gy fraction for SCLC
- Duration: 18 minutes (calibration 2 min, treatment 14 min, exit 2 min)
- Beam gating efficiency: 92.5%
- Breathing amplitude: 5.2 mm
- Marker displacement: 2.1 mm average
- Treatment interruptions: 0
- Investigational drug: Atezolizumab combination administered prior to RT per IND protocol
- Outcome: Successful completion. Full dose delivered.

Minute-by-minute summary:
- 06:18 - Patient positioned, marker block placed on chest
- 06:19 - Calibration complete, breathing pattern established at 5.2 mm amplitude
- 06:20 - Beam-on, field 1. Gating active.
- 06:24 - Field 1 complete (0.8 Gy delivered)
- 06:25 - Gantry rotation to field 2
- 06:26 - Beam-on, field 2
- 06:30 - Field 2 complete (0.7 Gy delivered)
- 06:31 - Gantry rotation to field 3
- 06:32 - Beam-on, field 3
- 06:34 - Field 3 complete (0.5 Gy delivered). Total: 2.0 Gy.
- 06:35 - Marker block removed, patient assisted to seated position
- 06:36 - Patient exits vault. Procedure complete.

### Humanoid Therapy Session (06:25-06:45)
- Patient: PAT-ODMND-0020
- Robot: HUMAN-01 (Humanoid, Instance 1)
- Location: Therapy Room 1 (Pediatric Wing)
- Procedure: Humanoid-assisted physical therapy for pediatric osteosarcoma patient
- Duration: 20 minutes
- Grip strength measurement: 8.2 kg (right hand)
- Balance score: 6.5/10
- Parent/guardian present throughout per 21 CFR Part 50 Subpart D
- Outcome: Successful session. Patient transitioned to REHAB-02.

Session summary:
- 06:25 - HUMAN-01 greeting sequence, rapport building with 11-year-old patient
- 06:28 - Warm-up exercises: gentle arm circles, wrist rotations
- 06:32 - Grip strength assessment: 8.2 kg right hand, 7.8 kg left hand
- 06:36 - Balance exercises: single-leg stance, tandem walking
- 06:38 - Balance scored at 6.5/10 (mild deficit consistent with treatment effects)
- 06:40 - Coordination drills: ball catch sequence, finger tracking
- 06:43 - Cool-down stretches
- 06:45 - Session complete. Patient transitioned to REHAB-02 for exoskeleton session.

### Rehabilitation Exoskeleton Session (06:48-07:xx)
- Patient: PAT-ODMND-0020
- Robot: REHAB-02 (Rehabilitation Exoskeleton, Instance 2)
- Location: Rehab Bay 2
- Procedure: Lower extremity assisted gait training
- Start time: 06:48 (continues into Hour 07)
- Parent/guardian present throughout
- Status at 06:59: In progress, 11 minutes elapsed

### Cobot Biopsy Session (06:34-06:46)
- Patient: PAT-ODMND-0021
- Robot: COBOT-03 (Cobot, Instance 3)
- Location: Biopsy Station 3
- Procedure: Forearm soft-tissue biopsy for Grade II sarcoma
- Duration: 12 minutes
- Needle repositionings: 2 (initial placement suboptimal for tissue quality)
- Sample quality: Grade A (adequate for full histopathological analysis)
- Tissue cores obtained: 4
- Local anesthetic: Lidocaine 1%, 5 mL
- Outcome: Successful. Samples sent to pathology.

Minute-by-minute summary:
- 06:34 - Patient positioned, forearm stabilized in biopsy cradle
- 06:35 - Ultrasound localization of target lesion by COBOT-03
- 06:36 - Local anesthetic administered
- 06:37 - First needle insertion, core sample 1 obtained
- 06:38 - Repositioning 1 (0.8 mm lateral adjustment for better tissue angle)
- 06:39 - Core sample 2 obtained
- 06:40 - Repositioning 2 (0.5 mm depth adjustment)
- 06:41 - Core samples 3 and 4 obtained
- 06:43 - Needle withdrawn, hemostasis achieved
- 06:44 - Pressure dressing applied
- 06:46 - Patient moved to recovery for 15-minute observation

### Steerable Needle Ablation (06:42-07:27, extends into Hour 07)
- Patient: PAT-ODMND-0022
- Robot: STEER-01 (Steerable Needle, Instance 1)
- Location: Ablation Suite 1
- Procedure: CT-guided radiofrequency ablation for HCC
- Total planned duration: 45 minutes
- Start: 06:42
- Status at 06:59: In progress (17 minutes elapsed, ablation active)

Minute-by-minute summary (Hour 06 portion):
- 06:42 - Patient positioned prone, CT scout acquired
- 06:44 - Planning CT completed, needle path calculated by AI
- 06:45 - Steerable needle insertion begins under CT fluoroscopy
- 06:47 - Needle tip at 8 cm depth, approaching tumor margin
- 06:48 - VASOVAGAL NEAR-MISS EVENT (see Adverse Events section)
- 06:50 - Patient stabilized, procedure resumed
- 06:52 - Needle positioned within tumor (14 mm HCC lesion, segment VI)
- 06:54 - CT confirmation of needle placement, ablation zone planning
- 06:56 - Radiofrequency ablation initiated, target temperature 60 C
- 06:58 - Ablation temperature reaching 55 C, on trajectory
- 06:59 - Procedure continues into Hour 07

### Imaging Assessment (06:55-07:10, extends into Hour 07)
- Patient: PAT-ODMND-0023
- Robot: IMAGE-01 (Imaging Assistant, Instance 1)
- Location: Imaging Bay 1
- Procedure: CT/ultrasound liver metastasis surveillance for Stage IV NSCLC
- Planned duration: 15 minutes
- Start: 06:55
- Status at 06:59: In progress (4 minutes elapsed)

## Patient Departures This Hour

| Patient ID | Time | Outcome | Notes |
|-----------|------|---------|-------|
| PAT-ODMND-0013 | 06:05 | Discharged | Post-RT treatment complete, no complications |
| PAT-ODMND-0015 | 06:10 | Discharged | Procedure complete, stable vitals |
| PAT-ODMND-0016 | 06:15 | Discharged | Procedure complete, stable vitals |

## Adverse Events

### Near-Miss Event: Vasovagal Response - PAT-ODMND-0022

- Time: 06:48
- Patient: PAT-ODMND-0022 (68M, HCC, Stage II)
- Context: During steerable needle ablation preparation, as needle tip approached
  8 cm depth
- Event: Brief vasovagal response. Heart rate dropped from 72 bpm to 52 bpm.
  Patient reported lightheadedness and mild nausea.
- Intervention: Procedure paused. Leg elevation applied immediately by attending
  nurse. STEER-01 needle position held stable (auto-lock engaged).
- Recovery: Heart rate recovered to 68 bpm within 2 minutes. Patient confirmed
  comfort and willingness to continue.
- Classification: NOT classified as adverse event per ICH E6(R3) Section 3.3.7.
  Documented as clinical observation. Heart rate remained above 50 bpm
  (bradycardia threshold) and resolved spontaneously with positional
  intervention only.
- Documentation: Entered in CRF as observation per 21 CFR 312.62. Safety
  monitoring board notified per protocol. STEER-01 auto-lock function performed
  as designed during the event, maintaining needle position within 0.1 mm.
- Follow-up: Continuous cardiac monitoring maintained for remainder of procedure.
  No recurrence through end of Hour 06.

## Investigational Drug Administrations

### PAT-ODMND-0019 - Atezolizumab Combination

- Patient: PAT-ODMND-0019 (56M, SCLC, Stage III, ECOG 1)
- Drug: Investigational atezolizumab combination per IND protocol
- Administration: IV infusion completed prior to RT session, per protocol
  schedule
- Timing: Pre-RT administration as specified in IND study design
- Documentation: Case report form completed per 21 CFR 312.62. Drug
  accountability log updated. Lot number, dose, route, time of administration,
  and administering clinician recorded.
- Monitoring: Patient monitored for infusion-related reactions during and after
  administration. No adverse reactions observed.
- Regulatory: IND protocol followed per 21 CFR Part 312 Subpart D. Sponsor
  notification of administration documented. Investigator brochure section on
  combination with RT referenced for safety monitoring parameters.

## Companion Robot Morning Activation

At 06:15, PAT-ODMND-0005 (8M, pediatric ALL) woke naturally. COMPN-03
transitioned from passive overnight monitoring to active morning interaction
mode. Activities included:
- 06:15 - Wake detection, gentle audio greeting
- 06:18 - Morning check-in dialogue, mood assessment (patient reported "okay")
- 06:22 - Interactive story continuation from prior evening session
- 06:30 - Transition to breakfast preparation support
- Mother joined from adjacent family area at 06:20

## Physician Assessment - PAT-ODMND-0003

At 06:30, the morning physician assessment was conducted for PAT-ODMND-0003
(61M, mediastinal tumor, post-surgical recovery):
- Surgical drain output: 25 mL overnight (decreasing trend, within expected range)
- Pain score: 2/10 (well-controlled)
- Vital signs stable (HR 74, BP 124/72, SpO2 96%, Temp 36.7 C)
- Surgical site: Clean, no signs of infection
- Assessment: Recovery progressing well. Discharge target revised to later today
  pending afternoon reassessment.

## Site Utilization

- Overall robot utilization: approximately 20% (6 of 29 robots active at peak)
- Queue lengths: 0 across all stations (no wait for robot availability)
- Average wait time: 4 minutes (check-in to procedure start)
- Robot cleaning cycles: 4 (RTPOS-02, TRACK-03, COBOT-03, HUMAN-01 post-procedure)

## Patient Census at 06:59

| Patient ID | Location | Status |
|-----------|----------|--------|
| PAT-ODMND-0003 | Recovery Bay 3 | Post-surgical recovery |
| PAT-ODMND-0005 | Pediatric Ward | Awake, COMPN-03 active interaction |
| PAT-ODMND-0014 | On-site | Continuing from prior hour |
| PAT-ODMND-0017 | On-site | Continuing from prior hour |
| PAT-ODMND-0018 | Discharge processing | Post-RT, awaiting discharge |
| PAT-ODMND-0019 | Discharge processing | Post-RT, awaiting discharge |
| PAT-ODMND-0020 | Rehab Bay 2 | REHAB-02 session in progress |
| PAT-ODMND-0021 | Recovery Bay 7 | Post-biopsy observation |
| PAT-ODMND-0022 | Ablation Suite 1 | STEER-01 ablation in progress |
| PAT-ODMND-0023 | Imaging Bay 1 | IMAGE-01 scan in progress |

Total patients on-site at 06:59: 10 (transition to 9 as P0018 completes discharge)

## Regulatory Compliance Notes

### ICH E6(R3) - Adaption
- Section 1.1.1: All procedures conducted in accordance with ethical principles
  and applicable GCP requirements. Morning ramp-up maintained identical safety
  standards to overnight operations despite increased patient volume.
- Section 2.9.1: Complete audit trails maintained for all six procedure sessions
  including beam-on times, dose delivery records, gating efficiency logs, biopsy
  sample tracking, and ablation parameters.
- Section 3.3.7: Vasovagal near-miss event for PAT-ODMND-0022 documented as
  clinical observation. Event did not meet threshold for adverse event
  classification. Full documentation maintained in trial master file.
- Section 4.2.1: Data capture for all sessions included synchronized UTC
  timestamps, robot telemetry, patient vitals, and procedure-specific metrics.

### 21 CFR Part 50 - Adaption
- Section 50.25: All six new patients had previously completed informed consent
  including Physical AI system disclosure, USL readiness scores, and right to
  non-Physical AI alternatives.
- Section 50.27: PAT-ODMND-0022 provided verbal reconfirmation of willingness
  to continue after vasovagal event. Documented by attending nurse and
  investigator.
- Subpart D: PAT-ODMND-0020 (11M, osteosarcoma) treated under pediatric
  protections. Parent/guardian present for both humanoid therapy and rehab
  exoskeleton sessions. Assent documented. IRB-approved pediatric protocol
  followed.

### 21 CFR Part 312 - Adaption
- Section 312.32: Safety reporting systems active. Vasovagal near-miss
  documented. Does not meet IND safety report threshold per Section 312.32(c)
  as it was not an adverse event.
- Section 312.62: Investigator recordkeeping maintained for all patients.
  PAT-ODMND-0019 IND drug administration documented with full accountability
  chain including lot number, dose, route, time, and administering clinician.
- Section 312.68: Records available for FDA inspection at all times. Morning
  shift handover included transfer of active patient documentation.

## Complementary Framework References

The Unification Standard Level (USL) framework (Kawchak, 2026;
DOI: 10.5281/zenodo.18778220) provides complementary robot technical
interoperability scoring. STEER-01's auto-lock function during the vasovagal
near-miss event demonstrated the safety engineering evaluated in USL
assessments. The needle maintained position within 0.1 mm during the 2-minute
pause, consistent with USL Intermediate band safety specifications.
See physical-ai-oncology-trials/unification/usl/paper/usl_oncology_trials.tex.

The single-patient cancer journey framework (Kawchak, 2026;
DOI: 10.5281/zenodo.19119939) demonstrated autonomous Physical AI trial
orchestration for an individual patient. PAT-ODMND-0020's combined
humanoid-to-rehab exoskeleton workflow represents a multi-robot sequential
handoff pattern not present in single-patient scenarios, demonstrating the
expanded orchestration complexity of multi-patient on-demand operations.
See physical-ai-oncology-trials/patient-journey/paper/patient_journey_paper.tex.
